Impact News +++ ANLEIHEN-Woche #KW34 – 2025: Energiekontor, JDC, The Platform Group, Aream, LEEF, Dt. Rohstoff,... (Anleihen-Finder) +++ PLATFORM GROUP Aktie +4,84%

COHERUS Aktie

>COHERUS Aktienkurs

0.9864 EUR +0.8% (Tradegate)

Ask: 1.065 EUR / 2816 Stück

Bid: 1.0255 EUR / 2925 Stück

Tagesumsatz: 6785 Stück

Realtime Kurs von 8 bis 22 Uhr!

COHERUS Aktie über LYNX handeln

Intraday

1 Jahr

>COHERUS Performance

1 Woche: +12,7%

1 Monat: +25,1%

3 Monate: +41,9%

6 Monate: -5,2%

1 Jahr: -18,6%

laufendes Jahr: -31,3%

>COHERUS Aktie

Name:

COHERUS ONCOLOGY DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US19249H1032 / A12ETZ

Symbol/ Ticker:

8C5 (Frankfurt) / CHRS (NASDAQ)

Kürzel:

FRA:8C5, ETR:8C5, 8C5:GR, NASDAQ:CHRS

Index:

Webseite:

https://www.coherus.com/

Profil:

Coherus Biosciences Inc. is a biotechnology compan..
>Volltext..

Marktkapitalisierung:

106.73 Mio. EUR

Unternehmenswert:

-48.95 Mio. EUR

Umsatz:

122.52 Mio. EUR

EBITDA:

-110.05 Mio. EUR

Nettogewinn:

-136.75 Mio. EUR

Gewinn je Aktie:

-1.18 EUR

Schulden:

46.45 Mio. EUR

Liquide Mittel:

186.14 Mio. EUR

Operativer Cashflow:

-90.85 Mio. EUR

Bargeldquote:

0.9

Umsatzwachstum:

-57.87%

Gewinnwachstum:

-393.85%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

COHERUS

Letzte Datenerhebung:

23.08.25

>COHERUS Kennzahlen

Aktien/ Unternehmen:

Aktien: 116.23 Mio. St.

Frei handelbar: 90.93%

Leerverk. Aktien: 27.9%

Rückkaufquote: -0.34%

Mitarbeiter: 228

Umsatz/Mitarb.: 1 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 336.01%

Bewertung:

KGV: -

KGV lG: -

KUV: 0.88

KBV: 1.06

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 54.27%

Gewinnmarge: -107.66%

Operative Marge: -93.08%

Managementeffizenz:

Gesamtkaprendite: -27.59%

Eigenkaprendite: -860.65%

>COHERUS Peer Group

Es sind 601 Aktien bekannt.

>COHERUS Chart & Kurs - NASDAQ

>COHERUS News

08.08.25 - 14:24	Intas Pharmaceuticals acquires Udenyca from Coherus BioSciences (PBR)
	This acquisition expands Intas and Accord's biosimilar portfolio approved by the FDA and expedites their growth in the global market. With the acquisition, Intas' US speciality business Accord The post Intas Pharmaceuticals acquires Udenyca from Coherus BioSciences appeared first on Pharmaceutical Business review....

08.08.25 - 04:12	Coherus (CHRS) Q2 Revenue Jumps 10% (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

08.08.25 - 01:45	Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
	Coherus Oncology (CHRS) delivered earnings and revenue surprises of -9.68% and +1.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

07.08.25 - 22:54	Coherus BioSciences Non-GAAP EPS of -$0.34 misses by $0.07, revenue of $10.25M beats by $0.97M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.08.25 - 22:42	Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
	– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 –...

31.07.25 - 22:48

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire EN)

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update....

30.05.25 - 14:03	Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics (GlobeNewswire EN)
	REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today to better align with its exclusive focus on proprietary innovative immuno-oncology medicines....

29.05.25 - 01:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Coherus BioSciences im Wert von 73881 USD (Insiderkauf)
	Wahlstrom, Mats - Aufsichtsrat - Tag der Transaktion: 2025-05-23...

27.05.25 - 14:33	STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer (PR Newswire)
	STC-15 has demonstrated durable clinical activity and tolerability to progress into a combination study with a checkpoint inhibitor Collaboration enables Phase 1b/2 study with STORM's lead product, STC-15 in combination with Coherus's next generation PD-1 inhibitor, LOQTORZI®......

27.05.25 - 14:33	Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) (GlobeNewswire EN)
	– First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor – – First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor –...

13.05.25 - 04:51	Coherus outlines $150M–$200M LOQTORZI NPC target while advancing pipeline through partnerships (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.05.25 - 01:00	Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
	Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -12.90% and 85.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...

12.05.25 - 22:39	Coherus BioSciences Non-GAAP EPS of -$0.35, revenue of $7.6M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.05.25 - 22:18	Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
	– Strategic transformation to innovative oncology completed in Q2 2025 –...

05.05.25 - 22:03

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 (GlobeNewswire EN)

REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update....

01.05.25 - 23:06	Coherus to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
	REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that the company will be webcasting its participation in the upcoming conferences:...

28.04.25 - 16:12	Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 (GlobeNewswire EN)
	– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab –...

14.04.25 - 14:31	Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio (PR Newswire)
	Finalization of acquisition reinforces Accord BioPharma and Intas' commitment to growth in the U.S. biosimilar market RALEIGH, N.C., April 14, 2025 /PRNewswire/ -- Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology,......

01.04.25 - 14:54	Coherus announces repurchase of about $170M of convertible notes (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

01.04.25 - 14:03	Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes (GlobeNewswire EN)
	– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture –...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Ein Politiker verschweigt oft auch das, was er nicht weiß. - Dr. Fritz P. Rinnhofer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram